Swedish Orphan Biovitrum AB (publ) (STO:SOBI)
Sweden flag Sweden · Delayed Price · Currency is SEK
274.00
+4.40 (1.63%)
Aug 7, 2025, 5:29 PM CET

Swedish Orphan Biovitrum AB Company Description

Swedish Orphan Biovitrum AB (publ), a biopharma company, provides medicines in the areas of haematology, immunology, and specialty care in Europe, North America, the Middle East, Asia, and Australia.

The company operates through three segments: Haematology, Immunology, and Specialty Care. It offers Alprolix for haemophilia B; ALTUVOCT for the treatment and prophylaxis of bleeding in patients with haemophilia A; Aspaveli/Empaveli for treating adult patients with paroxysmal nocturnal haemoglobinuria; Doptelet for the treatment of immune thrombocytopenia and thrombocytopenia; Elocta/Eloctate for the treatment and prophylaxis of bleeding in patients with haemophilia A; Gamifant for treating hemophagocytic lymphohistiocytosis; Kineret for the treatment of cryopyrin-associated periodic syndrome, rheumatoid arthritis, familial Mediterranean fever, deficiency of interleukin-1 receptor antagonist, and systemic juvenile idiopathic arthritis; Orfadin for hereditary tyrosinemia type 1 and alkaptonuria; Synagis for the prevention of serious lower respiratory tract infection caused by respiratory syncytial virus in infants and young children; VONJO, a kinase inhibitor indicated for the treatment of post-polycythemia vera or post-essential thrombocythemia myelofibrosis; and Zynlonta for treating adult patients with relapsed or refractory diffuse large and high grade B-cell lymphoma.

The company also provides other medicines, such as Akynzeo, Aloxi, Jyseleca, Kepivance, Tegsedi, and Waylivra, as well as develops drug substances for ReFacto AF/Xyntha for Pfizer.

The company has collaboration agreements with Sanofi, Apellis Pharmaceuticals, Inc., ADC Therapeutics SA, and Cartesian Therapeutics, Inc. Swedish Orphan Biovitrum AB (publ) was incorporated in 1939 and is headquartered in Stockholm, Sweden.

Swedish Orphan Biovitrum AB (publ)
Swedish Orphan Biovitrum AB logo
CountrySweden
Founded1939
IndustryDrug Manufacturers - Specialty & Generic
SectorHealthcare
Employees1,806
CEOGuido Oelkers

Contact Details

Address:
Norra Stationsgatan 93A
Stockholm
Sweden
Phone46 86 97 20 00
Websitesobi.com

Stock Details

Ticker SymbolSOBI
ExchangeNasdaq Stockholm
Share ClassClass A Shares
Fiscal YearJanuary - December
Reporting CurrencySEK
ISIN NumberSE0000872095
SIC Code2836

Key Executives

NamePosition
Dr. Guido Oelkers Ph.D.Chief Executive Officer and President
Henrik StenqvistChief Financial Officer
Torbjörn HallbergGeneral Counsel and Head of Legal Affairs
Daniel RankinHead of Strategy and Corporate Development
Lena BjurnerHead of Human Resources
Norbert OppitzHead of International
Sofiane FahmyHead of Europe
Duane H. BarnesHead of North America
Mahmood LadhaHead of Strategic Transformation Operations
Christine WesstromHead of Technical Operations